Dermatology · North Little Rock, AR
Dermatology and skin studies in North Little Rock, AR
8 recruiting studies have a site in North Little Rock.
8 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Regeneron Pharmaceuticals
- Location
- North Little Rock, AR + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- North Little Rock, AR + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- North Little Rock, AR + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- North Little Rock, AR + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- North Little Rock, AR + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- North Little Rock, AR + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
LEO Pharma
- Location
- North Little Rock, AR + 13 other US sites
- Eligibility basics
- Ages 6 mo–11
- RecruitingPhase 1
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Brexogen Inc.
- Location
- North Little Rock, AR + 2 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.